(Q36543800)

14 August 2017

1 reference

title

Cancer vaccines: preclinical studies and novel strategies (English)

1 reference

14 August 2017

3

Jeffrey Schlom

1 reference

14 August 2017

Claudia Palena

1

1 reference

14 August 2017

Scott I Abrams

series ordinal

2

1 reference

14 August 2017

James W Hodge

series ordinal

4

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Advances in Cancer Research

14 August 2017

published in

1 reference

14 August 2017

volume

95

1 reference

14 August 2017

page(s)

115-145

1 reference

Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Dendritic cells as vectors for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Anti-idiotype vaccine against cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

MHC restriction in three dimensions: a view of T cell receptor/ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

GM-CSF-based cellular vaccines: a review of the clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Vaccines for melanoma. Design strategies and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Poxviruses as expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Genetically engineered tumor cell vaccine in a head and neck cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Oral somatic transgene vaccination using attenuated S. typhimurium.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

GM-CSF-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Cytokines in cancer pathogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Adoptive-cell-transfer therapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

A New Twist on Autologous Cancer Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Cancer vaccines: between the idea and the reality

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Spontaneous adenocarcinoma mouse models for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Multiple costimulatory modalities enhance CTL avidity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Toll-like receptor control of the adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Immune effects and mechanisms of action of CpG motifs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Immature myeloid cells and cancer-associated immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

CpG DNA: security code for host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

In vivo manipulation of dendritic cells to induce therapeutic immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Selective induction of high avidity CTL by altering the balance of signals from APC.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Does the immune system see tumors as foreign or self?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

1 reference

7 January 2021

Exposing the immunology of naked DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

DNA vaccination against tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Developing recombinant and synthetic vaccines for the treatment of melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Determinant spreading and tumor responses after peptide-based cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Recombinant viruses as vaccines and immunological tools

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Progress in the development of immunotherapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Immunotherapy of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

B7-mediated costimulation and the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Models of T cell anergy: is there a common molecular mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Derangement of immune responses by myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Active immunization against cancer with dendritic cells: the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

From naive to memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Dendritic cell-derived exosomes as cell-free peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

On combining antineoplastic drugs with tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

Bacterial perturbation of cytokine networks

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995004-0

7 January 2021

10.1016/S0065-230X(06)95004-0

Identifiers

DOI

1 reference

14 August 2017

1 reference